Gene Therapy Access: The Pharmacy’s Role in the $3 Million Prescription
- 0:00 Why Access Breaks Differently
- 8:00 The Gene Therapy Access Map
- 18:00 Coverage, Coding, And Payment Logic
Practical shifts you can apply this week
-
Identify the pharmacy-controlled failure points that delay gene therapy initiati
Spot the handoffs and assumptions that quietly stall treatment before product ever moves.
-
Compare distribution, reimbursement, and site-of-care models for ultra-high-cost
See how payment pathway and care setting choices shape speed, risk, and who owns what.
-
Evaluate financial, operational, and clinical readiness before product is releas
Use a practical readiness lens before shipment, not after a preventable problem shows up.
-
Design a cross-functional pharmacy workflow for access, dispensing, and post-inf
Build checkpoints, stop points, and shared documentation across pharmacy, finance, and site teams.
-
Defend the pharmacy’s role in reducing time-to-treatment and avoidable financial
Leave with a clear case for why pharmacy is the operational hinge in one-time therapy access.
What we'll cover
-
0:00
Why Access Breaks Differently
Why one missed step can derail a one-time therapy, with examples from Zolgensma and real referral delays.
-
8:00
The Gene Therapy Access Map
Walk the journey from referral to administration and see where delays tend to hide.
-
18:00
Coverage, Coding, And Payment Logic
Compare medical vs pharmacy benefit, buy-and-bill, white bagging, PA logic, and reimbursement timing.
-
30:00
Financial Risk Before Shipment
Review patient liability, assistance, denials, spoilage, replacement terms, and cash-flow exposure.
-
40:00
Operational Readiness At Site
Cover certification, cold chain, chain of identity, labs, scheduling, and product arrival coordination.
-
49:00
Pharmacy Workflow That Holds
Outline the minimum workflow, escalation triggers, and shared documentation that keeps assumptions in check.
-
56:00
Metrics, Recap, And Q&A
Track preventable delay, financial exposure, and handoff quality, then map one high-risk workflow in your organization.
Questions people ask before registering
-
It is built for working professionals involved in specialty pharmacy, health-system pharmacy, reimbursement, access, finance, and clinical operations. If gene therapy touches your workflow, this will feel familiar.
-
No. We start with the access map and payment logic, then move into workflow design and risk points. If you know how complex therapies move through your organization, you will be fine.
-
Yes. Register and you should receive the replay after the session, so you can review the examples and timeline when your calendar behaves badly.
-
This session is educational. It focuses on practical access frameworks, real workflow failure points, and examples like Zolgensma and Hemgenix rather than a sales demo.
-
Check the registration details for the specific offering. If a certificate of attendance or CE is available, the host will outline eligibility and completion steps there.
-
A practical framework to map one live or upcoming gene therapy workflow, identify the highest-risk handoff, and bring pharmacy, finance, and operations together before treatment is delayed.